BioSkryb Genomics Partners with Research Instruments Pte Ltd to Bring Industry Leading Single-Cell Technologies to Singapore and Southeast Asia
Strategic distribution agreement with Research Instruments expands access to BioSkryb’s best-in-class single-cell multiomics portfolio throughout Southeast Asia
NUBURU Appoints John Bolton to its Board of Directors
Former National Security Advisor Joins NUBURU’s Board of Directors to Bolster Strategic and Commercial Development with Vast Defense Expertise
South 8 Technologies Secures Strategic Investment from Lockheed Martin Ventures
Funding will support the commercialization of LiGas®, South 8’s liquefied gas electrolyte technology that’s a safer, higher performance alternative to standard liquid electrolytes
Patent Awarded for Primary Template-Directed Amplification, Further Strengthening BioSkryb Genomics’ Core Technologies
The product solution combines HP’s new D100 Single Cell Dispenser with BioSkryb’s ResolveDNA® technology to enable the investigation of large single-cell genomics studies with unprecedented coverage and accuracy
BioFlyte Raises $5.4M in Series B Financing to Protect Critical Infrastructure from Airborne Biothreats
The product solution combines HP’s new D100 Single Cell Dispenser with BioSkryb’s ResolveDNA® technology to enable the investigation of large single-cell genomics studies with unprecedented coverage and accuracy
NUBURU Announces Contract With NASA for Next-generation Blue Laser Space Technology
The product solution combines HP’s new D100 Single Cell Dispenser with BioSkryb’s ResolveDNA® technology to enable the investigation of large single-cell genomics studies with unprecedented coverage and accuracy
Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1
EBT-101 is a potentially curative, one-time CRISPR-based treatment which makes two cuts in integrated retroviral DNA to remove large portions of the HIV genome and prevent HIV from escaping and reproducing
Excision’s ongoing Phase 1/2 trial is the first clinical evaluation of a CRISPR-based therapy targeting an infectious disease using a multiplexed in vivo gene editing approach
HIV-1 affects 38 million people worldwide, including 1.1 million in the US, with no available cures
BIOKÉ and BioSkryb Genomics announce a distribution agreement for the Benelux and Nordic countries
BIOKÉ and BioSkryb Genomics announce a distribution agreement for the Benelux and Nordic countries
Liquid Instruments and IEEE India to strengthen engineering education with workforce development and modern tools
The additional capital will help continue commercialization, execute the product development roadmap, and deliver improved capabilities.